By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


FibroGen, Inc. 

225 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-866-7200 Fax: 650-866-7202



Company News
FibroGen (FGEN) Granted Orphan Drug Designation For Pamrevlumab In The Treatment Of Pancreatic Cancer 6/22/2017 11:13:06 AM
European Patent Office Maintains FibroGen (FGEN) Patent Relating To Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology 6/5/2017 12:54:44 PM
FibroGen (FGEN) Reports First Quarter 2017 Financial Results 5/10/2017 11:09:09 AM
FibroGen (FGEN)'s Novel Anemia Treatment Meets Phase III Endpoints In China 1/31/2017 3:30:01 PM
Astellas (ALPMY) And FibroGen (FGEN) Announce First Patient Treated In Phase III Studies And Positive Phase II Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 7/26/2016 8:17:58 AM
FibroGen (FGEN) Gets $62 Million License Payment from Partner AstraZeneca PLC (AZN) 7/8/2016 6:41:08 AM
FibroGen, Inc. (FGEN) Release: Promising Phase II Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis 4/21/2016 8:25:15 AM
FibroGen, Inc. (FGEN) Announces Fiscal 2015 Financial Results 3/1/2016 8:32:47 AM
FibroGen, Inc. (FGEN) Publishes Encouraging Phase II Anemia Data Demonstrating Roxadustat’s Ability To Maintain Hemoglobin Levels In Patients With Chronic Kidney Disease 2/16/2016 10:46:46 AM
FibroGen, Inc. (FGEN) Appoints Jeffrey Edwards To Board Of Directors 10/30/2015 9:48:41 AM